Disc Medicine publishes corporate presentation on hematology pipeline targeting heme, iron pathways

• Disc Medicine highlighted late-stage development of bitopertin, an oral GlyT1 inhibitor aimed at reducing disease-causing PPIX in erythropoietic protoporphyria.
• Phase 3 APOLLO trial enrollment completed in March 2026; topline data expected in Q4 2026; 183 patients ages 12+ randomized 1:1.
• APOLLO co-primary endpoints: pain-free sunlight exposure time in the final month of treatment; % change in whole-blood metal-free PPIX at 6 months.
• Phase 2 AURORA data cited: 40% reduction in PPIX vs baseline; 75% lower phototoxic reaction rate vs placebo; 86% reported EPP “much better.”
• Pipeline update included iron-regulation antibodies DISC-0974 and DISC-3405 targeting hepcidin pathways for anemia and iron-restriction indications; both remain investigational.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.